GlycoMimetics Past Earnings Performance
Past criteria checks 0/6
GlycoMimetics has been growing earnings at an average annual rate of 4.1%, while the Biotechs industry saw earnings growing at 15.3% annually. Revenues have been declining at an average rate of 30.4% per year.
Key information
4.1%
Earnings growth rate
10.8%
EPS growth rate
Biotechs Industry Growth | -14.6% |
Revenue growth rate | -30.4% |
Return on equity | -96.1% |
Net Margin | -368,994.2% |
Next Earnings Update | 09 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How GlycoMimetics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 0 | -37 | 19 | 20 |
30 Sep 23 | 0 | -38 | 20 | 21 |
30 Jun 23 | 0 | -37 | 19 | 20 |
31 Mar 23 | 0 | -42 | 20 | 24 |
31 Dec 22 | 0 | -47 | 19 | 28 |
30 Sep 22 | 0 | -54 | 19 | 35 |
30 Jun 22 | 0 | -63 | 19 | 44 |
31 Mar 22 | 0 | -64 | 18 | 46 |
31 Dec 21 | 1 | -63 | 17 | 47 |
30 Sep 21 | 1 | -62 | 17 | 46 |
30 Jun 21 | 2 | -58 | 16 | 44 |
31 Mar 21 | 2 | -58 | 16 | 43 |
31 Dec 20 | 10 | -51 | 17 | 45 |
30 Sep 20 | 10 | -50 | 17 | 45 |
30 Jun 20 | 9 | -50 | 16 | 45 |
31 Mar 20 | 9 | -51 | 15 | 48 |
31 Dec 19 | 0 | -58 | 14 | 47 |
30 Sep 19 | 0 | -57 | 13 | 48 |
30 Jun 19 | 0 | -55 | 13 | 47 |
31 Mar 19 | 0 | -51 | 12 | 43 |
31 Dec 18 | 0 | -48 | 11 | 40 |
30 Sep 18 | 0 | -44 | 11 | 35 |
30 Jun 18 | 0 | -40 | 11 | 31 |
31 Mar 18 | 0 | -37 | 11 | 27 |
31 Dec 17 | 0 | -33 | 10 | 24 |
30 Sep 17 | 0 | -32 | 9 | 23 |
30 Jun 17 | 0 | -32 | 9 | 24 |
31 Mar 17 | 0 | -32 | 9 | 24 |
31 Dec 16 | 0 | -32 | 9 | 23 |
30 Sep 16 | 0 | -32 | 8 | 24 |
30 Jun 16 | 0 | -32 | 8 | 23 |
31 Mar 16 | 20 | -13 | 8 | 25 |
31 Dec 15 | 20 | -13 | 8 | 25 |
30 Sep 15 | 20 | -11 | 8 | 23 |
30 Jun 15 | 20 | -11 | 7 | 23 |
31 Mar 15 | 15 | -13 | 7 | 21 |
31 Dec 14 | 15 | -11 | 7 | 20 |
30 Sep 14 | 15 | -8 | 5 | 17 |
30 Jun 14 | 15 | -5 | 4 | 15 |
31 Mar 14 | 0 | -16 | 4 | 13 |
31 Dec 13 | 4 | -11 | 3 | 12 |
30 Sep 13 | 8 | -6 | 3 | 11 |
30 Jun 13 | 12 | -2 | 2 | 11 |
Quality Earnings: GKO is currently unprofitable.
Growing Profit Margin: GKO is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: GKO is unprofitable, but has reduced losses over the past 5 years at a rate of 4.1% per year.
Accelerating Growth: Unable to compare GKO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GKO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Return on Equity
High ROE: GKO has a negative Return on Equity (-96.06%), as it is currently unprofitable.